NICOTINELL PEPPERMINT LOZENGES nicotine (as nicotine polacrilex) 2 mg lozenge blister pack

Pays: Australie

Langue: anglais

Source: Department of Health (Therapeutic Goods Administration)

Ingrédients actifs:

nicotine polacrilex, Quantity: 13.33 mg (Equivalent: nicotine, Qty 2 mg)

Disponible depuis:

Orion Laboratories Pty Ltd T/A Perrigo Australia

DCI (Dénomination commune internationale):

Nicotine polacrilex

forme pharmaceutique:

Tablet, uncoated

Composition:

Excipient Ingredients: mannitol; potassium bicarbonate; aspartame; sodium alginate; sodium carbonate; magnesium stearate; xanthan gum; Flavour

Mode d'administration:

Buccal

Unités en paquet:

144, 108, 156, 216, 72, 36, 96, 168, 120, 132, 288

Type d'ordonnance:

Not Scheduled after consideration by Committee, Not scheduled. Not considered by committee

indications thérapeutiques:

Relief of nicotine withdrawal symptoms including cravings associated with smoking cessation. Nicotine Lozenges may also be used as part of a smoking reduction strategy by smokers who are unable or not ready to stop smoking abruptly as a step towards stopping smoking. If possible, when stopping smoking, should be used in conjunction with behavioural support program.

Descriptif du produit:

Visual Identification: Cream/white embossed biconvex round tablet with an odour of peppermint. Embossed with 'L344' on one face.; Container Type: Blister Pack; Container Material: PVC/PCTFE (Aclar)/Al; Container Life Time: 36 Months; Container Temperature: Store below 25 degrees Celsius

Statut de autorisation:

Licence status A

Date de l'autorisation:

2016-06-23